Filtered By:
Source: Molecular Cancer Therapeutics
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 96 results found since Jan 2013.
Predictive Biomarkers for IGF-1R/IR Inhibitor BMS-754807 in Colorectal Cancer
Insulin-like growth factor receptor 1 (IGF-1R)–targeting therapies are currently at an important crossroad given the low clinical response rates seen in unselected patients. Predictive biomarkers for patient selection are critical for improving clinical benefit. Coupling in vitro sensitivity testing of BMS-754807, a dual IGF-1R/IR inhibitor, with genomic interrogations in 60 human colorectal cancer cell lines, we identified biomarkers correlated with response to BMS-754807. The results showed that cell lines with BRAFV600E or KRASG13D mutation were resistant, whereas cell lines with wild-type of both KRAS and BRAF we...
Source: Molecular Cancer Therapeutics - February 9, 2015 Category: Cancer & Oncology Authors: Huang, F., Chang, H., Greer, A., Hillerman, S., Reeves, K. A., Hurlburt, W., Cogswell, J., Patel, D., Qi, Z., Fairchild, C., Ryseck, R.-P., Wong, T. W., Finckenstein, F. G., Jackson, J., Carboni, J. M. Tags: Companion Diagnostics and Cancer Biomarkers Source Type: research
Inhibition of Neuroblastoma Development by Targeting Midkine
Midkine (MDK) is a member of a new family of neurotrophic factors considered as rate-limiting growth and angiogenic factors implicated in the onset, invasion, and metastatic process of neuronal tumors, including neuroblastoma. We showed that all neuroblastoma cell lines highly expressed MDK, indicating that it is a critical player in tumor development, which may henceforth represent an attractive therapeutic target. We showed that the knockdown of MDK expression by siRNA led to a marked and significant decrease in neuroblastoma (IGR-N91 and SH-SY5Y) cell proliferation in vitro. Using a new strategy, we then evaluated the a...
Source: Molecular Cancer Therapeutics - January 13, 2015 Category: Cancer & Oncology Authors: Dianat, N., Le Viet, B., Gobbo, E., Auger, N., Bieche, I., Bennaceur-Griscelli, A., Griscelli, F. Tags: Cancer Biology and Signal Transduction Source Type: research
In Vivo KRAS Silencing with siRNA
This study highlights the potential translational impact of therapeutic RNA interference, which may have broad applications in oncology, especially for traditional "undruggable" targets. Mol Cancer Ther; 13(12); 2876–85. ©2014 AACR.
Source: Molecular Cancer Therapeutics - December 4, 2014 Category: Cancer & Oncology Authors: Pecot, C. V., Wu, S. Y., Bellister, S., Filant, J., Rupaimoole, R., Hisamatsu, T., Bhattacharya, R., Maharaj, A., Azam, S., Rodriguez-Aguayo, C., Nagaraja, A. S., Morelli, M. P., Gharpure, K. M., Waugh, T. A., Gonzalez-Villasana, V., Zand, B., Dalton, H. Tags: Small Molecule Therapeutics Source Type: research
ADAM9 in Gastric Cancer
Advanced gastric cancer is one of the most aggressive gastrointestinal malignancies, and ADAM (A disintegrin and metalloproteinase)-9 is a cell-surface membrane glycoprotein with oncogenic properties that is overexpressed in several cancers. Herein, we investigated the biologic mechanism of ADAM9 in the progression, proliferation, and invasion of gastric cancer. First, we detected ADAM's expression, processing, and protease activity in gastric cancer cells. Protease activity was moderately correlated with ADAM9 protein expression, but was better related to a processed smaller molecular weight (84 kDa) form of ADAM9. Knockd...
Source: Molecular Cancer Therapeutics - December 4, 2014 Category: Cancer & Oncology Authors: Kim, J. M., Jeung, H.-C., Rha, S. Y., Yu, E. J., Kim, T. S., Shin, Y. K., Zhang, X., Park, K. H., Park, S. W., Chung, H. C., Powis, G. Tags: Cancer Biology and Signal Transduction Source Type: research
Targeting MLL5{beta} for Cervical Cancer Therapy
In this report, we investigated the potential of RNAi-mediated silencing of MLL5β through the use of MLL5β-siRNA as a novel therapeutic strategy for HPV16/18-positive cervical cancer. We observed concurrent downregulation of E6 and E7 after MLL5β silencing, leading to growth inhibition via the activation of apoptosis and senescence in the HeLa cell model. This corresponded with the enhanced antitumor effects of MLL5β-siRNA compared with E6- or E7-siRNA single treatments. Significant reduction in tumor size after MLLβ-siRNA treatment in the HeLa xenograft tumor model further emphasized the importanc...
Source: Molecular Cancer Therapeutics - November 3, 2014 Category: Cancer & Oncology Authors: Nin, D. S., Yew, C. W., Tay, S. K., Deng, L.-W. Tags: Small Molecule Therapeutics Source Type: research
CDK4/6 Inhibitor Reduces Human Liposarcoma Growth
In this study, we explored the role of CDK4 and the effects of NVP-LEE011 (LEE011), a novel selective inhibitor of CDK4/CDK6, on a panel of human liposarcoma cell lines and primary tumor xenografts. We found that both CDK4 knockdown by siRNA and inhibition by LEE011 diminished retinoblastoma (RB) phosphorylation and dramatically decreased liposarcoma cell growth. Cell-cycle analysis demonstrated arrest at G0–G1. siRNA-mediated knockdown of RB rescued the inhibitory effects of LEE011, demonstrating that LEE011 decreased proliferation through RB. Oral administration of LEE011 to mice bearing human liposarcoma xenograft...
Source: Molecular Cancer Therapeutics - September 2, 2014 Category: Cancer & Oncology Authors: Zhang, Y.-X., Sicinska, E., Czaplinski, J. T., Remillard, S. P., Moss, S., Wang, Y., Brain, C., Loo, A., Snyder, E. L., Demetri, G. D., Kim, S., Kung, A. L., Wagner, A. J. Tags: Small Molecule Therapeutics Source Type: research
